Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
In anticipation of the raft of earnings releases and analyst and investor calls that will take place in the next few weeks, the U.S. Securities and Exchange Commission (SEC) issued a public statement in which SEC Chairman Jay Clayton and Director of the Division of Corporation Finance William Hinman urge issuers to provide robust, forward-looking disclosures regarding the impact of COVID-19 in their upcoming earnings releases and analyst and investor calls.
Schiff Hardin Employment Law Landscape
In recent weeks, an increasing number of state legislatures have taken drastic measures to force the insurance industry to shoulder much of the burden of the economic downturn brought on by the global COVID-19 pandemic.
Schiff Hardin Product Liability and Mass Torts Blog
Turf magazine
Like new cases of COVID-19, the number of business interruption suits appears to be increasing exponentially. In the last few weeks, dozens of plaintiffs in at least six lawsuits across four states have sought insurance coverage for business losses associated with the COVID-19 outbreak.
Law360
On March 25, the U.S. Securities and Exchange Commission (SEC) granted public company regulatory relief and issued Staff guidance regarding disclosure obligations in light of the continued complications associated with the COVID-19 pandemic.
Schiff Hardin Energy & Environmental Law Adviser
Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
